Eseng Lai MD PhD
Diabetes, Lipid Metabolism
Executive Director, Clinical Research Merck Research Laboratories
Join to View Full Profile
525 E 68th StNew York, NY 10065
Phone+1 212-746-4745
Dr. Lai is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
New York Presbyterian Hospital (Cornell Campus)Fellowship, Endocrinology, Diabetes, and Metabolism, 1987 - 1988- New York Presbyterian Hospital (Cornell Campus)Fellowship, Endocrinology, Diabetes, and Metabolism, 1986 - 1987
- New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 1983 - 1986
Albert Einstein College of MedicineClass of 1983
Certifications & Licensure
NY State Medical License 1984 - 2028
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Publications & Presentations
PubMed
- Phase 1 Study Evaluating the Effects of Single-Dose Frespaciguat, an Inhaled Soluble Guanylate Cyclase Stimulator, Co-administered with Multiple-Dose Sildenafil on Sys...Ednan K Bajwa, Dawn Cislak, John Palcza, Tom Reynders, Jenny Barthson
Clinical Pharmacology in Drug Development. 2026-02-01 - 4 citationsSafety, pharmacokinetics, and pharmacodynamics of MK-6194, an IL-2 mutein designed to selectively activate regulatory T cells: single ascending dose and multiple ascen...Johannes F Scheid, Kiki Cunningham-Bussel, Nancy Kim, Shiuli Agarwal, Garrett Nieddu
Immunohorizons. 2025-03-26 - 2 citationsA randomized phase 1 study of safety, tolerability, and pharmacokinetics of MK-1088, a novel dual adenosine receptor antagonist, in healthy adult participants.Pranav Gupta, Manash Chatterjee, Yeonil Kim, Kathleen Deschamps, Lieselotte Lemoine
Investigational New Drugs. 2024-10-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
